Dr. Mark Adler, Institute Director, heads the Genomic Oncology Diagnostics and Second Opinion Initiative, a new generation-platform for developing treatments tailored to the individual patient. It involves the application of sensitive genomic tests to the determination of a tumor’s drug sensitivity and resistance. In addition a person’s hereditary traits and a tumor’s genetic signature will be used to determine how best to eliminate a given cancer with a specific therapy or agent.
Mark Adler, M.D.
Dr. Mark Adler co-founded the San Diego Cancer Research Institute, 501(c)(3). He founded and was CEO and Medical Director of the San Diego Cancer Center. He served as a Director of CareInsite (NASDAQ:CARI) until its merger with Healtheon and currently serves as a Director of WebMD (NASDAQ:WBMD) and HLTH (NASDAQ:HLTH). He has served as a biotechnology development consultant for a number of international pharmaceutical firms and biotechnology companies. Dr. Adler received his B.A. at Yale University (1978), Phi Beta Kappa, Summa Cum Laude. He received his M.D. degree from the University of Pennsylvania in 1982; his internship and residency was in Internal Medicine at Presbyterian-University of Pennsylvania Hospital. His subspecialty training in both Hematology and Oncology was at UCSD. He is Board Certified both in Internal Medicine and Medical Oncology. In 1985, under a National Research Service Award he served as Fellow in Tumor Immunology at the Wistar Institute. In 1987, he was a recipient of the NIH Physician-Scientist Award. From 1987 to 1992 he served as Physician-Scientist Fellow at the University of California-San Diego Medical Center. His research interests and publications have focused on the molecular biology and genes underlying cancer and cellular senescence.